NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

被引：0
|
作者：
Munechika Enjoji
Kazuyuki Machida
Motoyuki Kohjima
Masaki Kato
Kazuhiro Kotoh
Kazuhisa Matsunaga
Manabu Nakashima
Makoto Nakamuta
机构：
[1] Fukuoka University,Faculty of Pharmaceutical Sciences
[2] National Hospital Organization,Clinical Research Center, Kyushu Medical Center
[3] National Hospital Organization,Department of Gastroenterology, Kyushu Medical Center
[4] Kyushu University,Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences
来源：
Lipids in Health and Disease | / 9卷
关键词：
Ezetimibe; Nonalcoholic Fatty Liver Disease; NAFLD Patient; Ursodiol; Ezetimibe Treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Clinical effectiveness of ezetimibe for a non-obese patient with nonalcoholic fatty liver disease
    Enjoji, Munechika
    Tanaka, Masatake
    Miyazaki, Masayuki
    Higuchi, Nobito
    Kato, Masaki
    Kotoh, Kazuhiro
    Matsunaga, Kazuhisa
    Nishinakagawa, Takuya
    Machida, Kazuyuki
    Nakashima, Manabu
    Nakamuta, Makoto
    AMERICAN JOURNAL OF CASE REPORTS, 2009, 10 : 148 - 151
  • [2] Identification of a Novel NPC1L1 Inhibitor from Danshen and Its Role in Nonalcoholic Fatty Liver Disease
    Xia, Donghai
    Jiang, Xuan
    Xie, Xiaomin
    Zhou, Han
    Yu, Dongping
    Jin, Gaowa
    Ye, Xianlong
    Zhu, Shenglong
    Guo, Zhimou
    Liang, Xinmiao
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (06)
  • [3] Comparison between obese and non-obese nonalcoholic fatty liver disease
    Chan, Wah-Kheong
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 : S58 - S67
  • [4] Lean or non-obese nonalcoholic fatty liver disease patients: Are they really lean?
    Han, Eugene
    Lee, Yong-ho
    CLINICAL AND MOLECULAR HEPATOLOGY, 2023, 29 (04) : 980 - 983
  • [5] Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis
    Lee, Da Hyun
    Han, Dai Hoon
    Nam, Ki Taek
    Park, Jeong Su
    Kim, Soo Hyun
    Lee, Milim
    Kim, Gyuri
    Min, Byung Soh
    Cha, Bong-Soo
    Lee, Yu Seol
    Sung, Su Haeng
    Jeong, Haengdueng
    Ji, Hye Won
    Lee, Moon Joo
    Lee, Jae Sung
    Lee, Hui-Young
    Chun, Yoomi
    Kim, Joungmok
    Komatsu, Masaaki
    Lee, Yong-ho
    Bae, Soo Han
    FREE RADICAL BIOLOGY AND MEDICINE, 2016, 99 : 520 - 532
  • [6] Risk Factors of Nonalcoholic Fatty Liver Disease and Liver Fibrosis in Non-Obese Patients with Obstructive Sleep Apnea
    Lian, Ningfang
    Wu, Jiawei
    Wang, Biying
    Lin, Su
    Huang, Jiefeng
    Chen, Jia
    Lin, Qichang
    NATURE AND SCIENCE OF SLEEP, 2022, 14 : 2143 - 2149
  • [7] Non-alcoholic Fatty Liver Disease in Non-obese Patients
    Christopher J. Schmoyer
    Mohammad S. Siddiqui
    Current Hepatology Reports, 2017, 16 (4) : 382 - 390
  • [8] Metabolic status indicators and influencing factors in non-obese, non-centrally obese nonalcoholic fatty liver disease
    Huang, Zhipeng
    Wei, Donghong
    Yu, Xueping
    Huang, Zicheng
    Lin, Yijie
    Lin, Wenji
    Su, Zhijun
    Jiang, Jianjia
    MEDICINE, 2023, 102 (06)
  • [9] Development and validation of a nomogram for predicting nonalcoholic fatty liver disease in the non-obese Chinese population
    Wang, Jiao
    Tang, Yunliang
    Peng, Kaili
    Liu, Honghong
    Xu, Jixiong
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2020, 12 (10): : 6149 - 6159
  • [10] Ezetimibe, a NPC1L1 inhibitor, attenuates neuronal apoptosis through AMPK dependent autophagy activation after MCAO in rats
    Yu, Jing
    Li, Xue
    Matei, Nathanael
    McBride, Devin
    Tang, Jiping
    Yan, Min
    Zhang, John H.
    EXPERIMENTAL NEUROLOGY, 2018, 307 : 12 - 23
12345